American Century Companies’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-72,508
Closed -$108K 2685
2022
Q4
$108K Sell
72,508
-323,238
-82% -$718K ﹤0.01% 2444
2022
Q3
$1.48M Sell
395,746
-177,412
-31% -$855K ﹤0.01% 1549
2022
Q2
$2.84M Buy
573,158
+38,494
+7% +$254K ﹤0.01% 1311
2022
Q1
$4.39M Buy
534,664
+114
+0% +$984 ﹤0.01% 1142
2021
Q4
$5.39M Buy
534,550
+17,358
+3% +$225K ﹤0.01% 1033
2021
Q3
$8.2M Buy
517,192
+114,438
+28% +$2.4M 0.01% 901
2021
Q2
$9.58M Buy
+402,754
New +$9.35M 0.01% 828

Other funds holding NPCE

American Century Companies's NPCE Position: Q1 2023 in Review

American Century Companies sold out of Neuropace (NPCE) in Q1 2023, closing a stake of 72,508 shares — an estimated $108K sold.

American Century Companies first reported a position in NPCE in Q2 2021 and held it in 7 quarters. The position peaked at $9.58M in Q2 2021. 24 funds tracked by Wall St. Rank hold NPCE as of Q1 2023.

  • American Century Companies reported no remaining Neuropace position as of Q1 2023 after selling out during the quarter.
  • American Century Companies sold 72,508 Neuropace shares in Q1 2023, an estimated $108K.
  • American Century Companies first reported a position in Neuropace in Q2 2021 and held it in 7 quarters.
  • American Century Companies's Neuropace position peaked at $9.58M in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Neuropace as of Q1 2023.

Based on American Century Companies's 13F filing for Q1 2023, filed 11 May 2023.